Aspira Women's Health (AWH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 May, 2026Executive summary
Supplement corrects errors in previously reported beneficial ownership for two directors and updates executive officer changes as of April 2026.
Brian Hungerford departed as Chief Financial Officer on April 26, 2026; Sandra Milligan left as Interim CEO in early 2025.
Voting matters and shareholder proposals
Proxy voting instructions already submitted remain valid unless shareholders choose to change their vote.
Board of directors and corporate governance
Updated table details beneficial ownership for all directors and executive officers as of April 20, 2026.
All directors and executive officers as a group hold 9.4% of outstanding shares.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aspira Women's Health
- Revenue fell 15% year-over-year, with improved net loss but ongoing liquidity concerns.AWH
Q2 2026 - AI-driven diagnostics improve detection and reduce surgeries in women's health.AWHInvestor presentation
- Net income reached $676,000 despite a 14% revenue drop, but liquidity risks persist.AWHQ1 2026
- Director elections, executive pay, stock plan amendment, and auditor ratification up for vote.AWHProxy filing
- Proxy covers director elections, executive pay, stock plan amendment, and auditor ratification.AWHProxy filing
- Flat revenue, improved margins, and halved operating loss, but significant going concern risk remains.AWHQ4 2025
- AI-driven diagnostics advance women's health, improving outcomes and financial performance.AWHInvestor presentation
- $10M ARPA-H funding accelerates AI diagnostics for ovarian cancer and endometriosis.AWHInvestor Day 2024
- Q2 2024 saw 3% higher OvaSuite test volume, 48% OvaWatch growth, and new funding amid ongoing losses.AWHQ2 2024